Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + trifluridine tipiracil
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cetuximab + trifluridine tipiracil is a combination therapy used primarily in the treatment of metastatic colorectal cancer (mCRC), particularly in patients with RAS wild-type tumors who have progressed after standard therapies. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in cell proliferation and survival. Trifluridine tipiracil (also known as TAS-102) is an oral antineoplastic agent composed of two components: trifluridine, a thymidine-based nucleoside analog that incorporates into DNA and disrupts DNA synthesis, and tipiracil, which inhibits thymidine phosphorylase to increase the bioavailability of trifluridine. The combination has been investigated as a rechallenge strategy for patients previously treated with anti-EGFR agents and standard chemotherapies[1][2][3]. Clinical studies suggest this regimen can improve disease control rates in refractory mCRC.
- Brand names
- ErbituxLonsurf
- Other names
- cetuximab + trifluridine/tipiracilcetuximab plus TAS-102FTD/TPI plus cetuximab
02
Targets
DNATYMP (Thymidine phosphorylase)EGFR T790M (Epidermal growth factor receptor T790M mutant)TS (Thymidylate synthase)
Beyond the preview
Go deeper on cetuximab + trifluridine tipiracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + trifluridine tipiracil.